Postoperative Pain Management Market By Type of Drug (Nonsteroidal anti-inflammatory drugs (NSAIDs), Opioids, Local anesthetics, Anticonvulsants, Antidepressants, and Others (acetaminophen, ketamine, etc.)}; By Mode of Administration (Oral, Injectable, Transdermal, Intranasal, Others (rectal, sublingual, etc.)}; By End-user Type (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), Home Care Settings); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Market Analysis, Trends, Opportunity and Forecast, 2023-2033

Postoperative Pain Management Market Insights

Global postoperative pain management market witnessed a market value of USD 36.2 billion in 2023 and is estimated to reach USD 60.3 billion in 2033, registering a compound annual growth rate (CAGR) of 5.2% between 2023 and 2033. Medicines, devices, and procedures used to manage pain after surgery are known as the postoperative pain management market. Neurostimulators, infusion pumps, and pain relief patches are some of the postoperative pain management devices. These devices aim to provide targeted pain relief and reduce the need for systemic medications. Postoperative pain management also includes radiofrequency ablation, nerve blocks, and epidural injections. These procedures can be effective in patients who do not respond well to other forms of pain relief because they target specific nerves or areas of the body to relieve pain.

It is an important part of the overall pain treatment market and is expected to expand in the coming years due to the increase in the number of procedures worldwide, the increasing prevalence of chronic diseases, and the development of advanced pain treatments. Nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and local anesthetics are the most commonly used drug treatments. Physical therapy, acupuncture, and spinal cord stimulation are non-drug treatments.

Postoperative Pain Management Market Key Drivers

Several factors are driving the growth of the postoperative pain management market:

• Advancements in pain operation ways: Increased demand for advanced pain operation ways similar to whim-whams blocks and epidural injections, furnishing cases with further targeted and effective pain operation styles.
• Development of new and innovative treatments: The development of new treatment styles similar to targeted medicine delivery systems is anticipated to further drive the request expansion.
• Growing growing population: The frequency of habitual pain rises as the population periods, adding to the need for pain operation treatments.
• Increasing mindfulness of pain management: After surgery, cases are getting more apprehensive of how important pain operation is and are demanding better options for pain relief. thus, more advanced pain relief styles and biases are used.
• Boosting healthcare expenditure: Advanced pain operation ways and bias are getting decreasingly popular as public and private associations have made significant investments in healthcare structure and technology.
• Increasing frequency of chronic diseases & surgical procedures: Due to the need for surgery for habitual conditions similar to cancer, arthritis, and cardiovascular conditions, the need for postoperative pain operation is adding.

Postoperative Pain Management Market Segmentation

The global market for postoperative pain management can be segmented in many ways such as:

• By Type of Drug
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Opioids
  • Local anesthetics
  • Anticonvulsants
  • Antidepressants
  • Others (acetaminophen, ketamine, etc.)
• By Mode of Aadministration
  • Oral
  • Injectable
  • Transdermal
  • Intranasal
  • Others (rectal, sublingual, etc.)
• By End-user Type
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Home Care Settings
• By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East, and Africa

Postoperative Pain Management Regional Synopsis

The global market with pain prevention is expected to be significantly expanded. More and more surgical procedures, an aging population, and an increasing understanding of effective pain prevention are the driving force of the market. North America is expected to dominate the postoperative pain treatment market, followed by Europe. The market is expected to grow at a CAGR of 4.5% (2020-2026) during the forecast period and reach $9.5 billion by 2026, with the majority of growth expected to be in the US. Germany is expected to be the largest contributor to the European market and is projected to grow at a CAGR of 4.3% (2020-2026) to reach $7.3 billion by 2026.

The Asia Pacific market is expected to witness the highest annual growth rate due to rising healthcare consumption and the growing population in the region. The market is expected to register a CAGR of 5.2% during the forecast period (2020-2026). The market is expected to be worth $6.2 billion by 2026, with China having the largest market share. An increasing number of surgical procedures, an aging population, and increasing awareness of the importance of effective pain management are expected to drive significant growth in Latin America, the Middle East, and Africa. The Latin American market is expected to be worth $2.1 billion by 2026, with Brazil accounting for the majority with a CAGR of 4.1% (2020-2026). The Middle East and Africa market is expected to grow at a CAGR of 3.9% (2020-2026) to reach a value of $1.7 billion by 2026.

Postoperative Pain Management market share and manufacturer in Japan

In Japan, the postoperative pain treatment market was valued at $554.62 million in 2020 and is expected to reach $856.52 million by 2027, growing at a CAGR of 6.3% between 2021 and 2027. Astellas Pharma Inc., Daiichi Sankyo Company Limited, and Takeda Pharmaceutical Company Limited were some of the major players in the market. Opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and local anesthetics are among the many post-operative pain relievers offered by these players and command significant market share. Concerns about the opioid epidemic and the potential for addiction and abuse associated with opioid use have also led to a growing trend in the development of non-opioid analgesics such as nerve blocks and neuromodulation devices.

Postoperative Pain Management Market Key Research and Development:

Because it drives invention and leads to the creation of new and advanced pain operation options, exploration and development( R&D) is a significant element of the postoperative pain operation request. There has been a growing focus on the creation of druthers to opioid pain operations in response to the growing enterprises about opioid dependence and abuse. This includes the use of indispensable curatives( similar as neurostimulation) and the development of new medicines( similar as CGRP impediments). There's growing interest in customized pain maps that include individual treatment of specific exacerbations. This involves using biomarkers and inheritable tests to find cases that may respond more or worse to certain treatments.

To give further effective pain relief with smaller side goods, experimenters are exploring the concept of "combination remedy", which uses multiple medicines with different mechanisms of action. Transdermal patches and sustained-release lozenge forms are two exemplifications of new medicine delivery systems being developed to ameliorate the delivery of pain specifics. Digital curatives similar to virtual reality and mobile apps are being explored as a means of reducing pain and perfecting patient issues.

Postoperative Pain Management Market Challenges:

There are several challenges facing the postoperative pain management market.

1. Alternative therapies: Alternative pain management methods like acupuncture and herbal remedies are growing in popularity in Japan, attracting patients who are seeking alternatives to more traditional medications.
2. High treatment costs: In addition, high treatment costs for some medications and non-pharmacological treatments for pain can restrict their use, which limits the effectiveness of alternative pain management methods.
3. Insufficient awareness: Despite increasing awareness of the benefits of effective pain management, some healthcare professionals and patients still lack awareness and improper pain management can result in prolonged recovery time or even failure of treatment altogether.
4. Limited effectiveness of existing treatments: Many current pain treatments do not work for all patients and can have serious side effects. This may limit their use and increase the need for new treatments.
5. Opioid abuse and dependence: Opioids are subject to abuse and can lead to addiction, which in turn affects the market for these products.
6. Regulatory barriers: Japan's regulatory environment can be challenging for players in the postoperative pain treatment market, due to lengthy and expensive approval processes for medical devices and drugs.
7. Reimbursement issues: Payers are not always willing to pay for certain pain management treatments, which limits their use and affects the market.
8. Stigma of pain management: The use of opioids, especially as a form of pain relief, is often frowned upon. This may affect the market and prevent some patients from seeking treatment.

Postoperative Pain Management Market Key Players

Some of the key players in the market include:

Abbott Laboratories: The company produces products such as Brufen, Tramal, and Humira for pain management after surgery. For example, spinal cord stimulation therapy is an option for non-opioid pain management in which Abbott invests.

Cadila Healthcare Ltd.: This Indian multinational pharmaceutical company develops and markets products in various therapeutic areas including pain management products such as Naproxen, Paracetamol, and Diclofenac.

Cipla Ltd.: Cipla Ltd.'s portfolio for pain management includes Diclofenac Sodium, Ibuprofen, and Paracetamol.

Eli Lilly and Company: Postoperative pain management solutions, such as Olumiant and Cymbalta, are in the company's portfolio. In addition, Eli Lilly is investing in the creation of new pain management options, like its CGRP inhibitor for migraine treatment.

Johnson & Johnson Services Inc.: Johnson & Johnson is a global healthcare company that manufactures pharmaceuticals, medical devices, and consumer healthcare products. Products such as Duragesic, Nucynta, and Ultram are part of the company's portfolio for postoperative pain management; it's also working on new formulations of these drugs.

Lupin Limited: Lupin is an Indian pharmaceutical company that develops and markets pain management products, including Tramadol, Celecoxib and Diclofenac.

Merck & Co. Inc.: Merck is a major international pharmaceutical company that creates and sells many types of pain management products, including Nuromol and Arcoxia. In addition, Merck is investing in non-opioid analgesics for the treatment of migraine using CGRP inhibitors.

Pfizer Inc.: Pfizer is a multinational pharmaceutical company that focuses on pain management in other therapeutic areas with products including Celebrex, Lyrica, and Tanezumab. In addition to traditional pain relief products, Pfizer is also investing in the development of non-opioid pain treatment options.

Sun Pharmaceutical Industries Ltd.: Sun Pharma is a multinational pharmaceutical company located in India that creates and sells products in therapeutic areas, including pain management. Dolanzen, Ketorol DT, and Tramadol are three of the products in its postoperative pain management portfolio.